Core Viewpoint - BioVaxys Technology Corp. and Adiverna LLC have entered into a Research Agreement to develop mRNA-based vaccines for companion animals, marking a significant advancement in veterinary healthcare [1][2]. Group 1: Company Overview - BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company focused on novel immunotherapies based on the DPX™ immune-educating technology platform [9]. - Adiverna LLC is dedicated to advancing veterinary medicine through cutting-edge mRNA-based vaccines and therapies, utilizing proprietary technology to enhance the health of companion animals [11][14]. Group 2: Technology and Innovation - Adiverna employs artificial intelligence to design and optimize mRNA sequences for vaccines tailored for companion animals, a groundbreaking approach as no mRNA vaccines are currently approved for these animals [2][12]. - The BioVaxys DPX platform offers a novel non-systemic mechanism of action for vaccine delivery, enhancing immune response by targeting lymphatic nodes without releasing active ingredients at the injection site [3][4]. Group 3: Market Potential - The global rabies veterinary vaccines market is valued at approximately US$785 million in 2024 and is projected to reach around US$1.1 billion by 2030, growing at a CAGR of 5.8% [7]. - The broader dog vaccine market, which includes canine leptospirosis vaccines, was valued at approximately US$2.10 billion in 2025, while the feline vaccines sector is projected to grow from US$1.77 billion in 2025 to US$3.28 billion by 2034 [7]. Group 4: Advantages of mRNA Vaccines - DPX-formulated mRNA vaccines are expected to provide longer-lasting immunity with fewer doses compared to traditional vaccines, along with rapid and durable neutralizing antibody responses [4][5]. - Adiverna's mRNA platform has significant dose-sparing potential, reducing the amount of vaccine required while still eliciting robust immune responses [2][4].